文献速递白血病造血干细胞移植与细胞治疗

双特异性抗体选择性招募γδ T细胞治疗急性髓系白血病

Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
PubMed 文献 · Leukemia · 2021-02-01

针对急性髓系白血病(AML)免疫治疗中泛CD3+ T细胞重定向疗效有限且毒性严重的问题,研究者设计了可同时结合Vγ9Vδ2+ γδ T细胞受体Vγ9链与AML靶抗原CD123的双特异性抗体(Anti-TRGV9/anti-CD123),选择性招募Vγ9+ γδ T细胞而非泛T细胞。结果表明该原型双特异性抗体可选择性激活Vγ9+ γδ T细胞、促进其与肿瘤细胞形成细胞-细胞结合物,并在体外和体内介导γδ T细胞对表达肿瘤抗原细胞的细胞毒性。

要点

  • 双特异性抗体Anti-TRGV9/anti-CD123可选择性激活Vγ9+ γδ T细胞。
  • 该抗体促进Vγ9+ γδ T细胞与肿瘤细胞形成细胞-细胞结合物。
  • 该抗体在体外和体内介导γδ T细胞对表达肿瘤抗原细胞的细胞毒性。

核心结论

  • 选择性将Vγ9+ γδ T细胞重定向至AML原始细胞具有治疗AML的免疫治疗潜力,值得进一步探索。

研究设计与样本

  • 研究设计为原型双特异性抗体(Anti-TRGV9/anti-CD123)的体外和体内功能验证。

主要发现

  • 该双特异性抗体以CD69和CD25表面表达及细胞内颗粒酶B表达为指标,选择性激活Vγ9+ γδ T细胞。
  • 该抗体选择性招募Vγ9+ γδ T细胞与肿瘤细胞形成细胞-细胞结合物,表明效应细胞与靶肿瘤细胞的选择性有效结合。
  • 该抗体在体外和体内介导γδ T细胞对表达肿瘤抗原细胞的细胞毒性。

关键数值与推荐

  • Vγ9+ γδ T细胞激活以CD69和CD25表面表达及细胞内颗粒酶B表达为判断指标。

临床怎么用

  • 该策略为AML患者提供了一种选择性重定向Vγ9+ γδ T细胞的潜在免疫治疗方向,尚需进一步临床探索。

局限性

  • 研究结果为原型双特异性抗体的临床前验证,尚未在AML患者中评估疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant progress over the last few decades in the treatment of acute myeloid leukemia (AML), there still remains a major unmet medical need for this disease. Immunotherapy approaches for redirecting pan CD3+ T cells to target leukemia blasts have shown limited efficacy in clinical trials and often accompanied with severe toxicity in AML patients. We designed an alternative engager molecule (Anti-TRGV9/anti-CD123), a bispecific antibody that can simultaneously bind to the Vγ9 chain of the Vγ9Vδ2+ γδ T cell receptor and to AML target antigen, CD123, to selectively recruit Vγ9+ γδ T cells rather than pan T cells to target AML blasts. Our results suggest that prototypic bispecific antibodies (a) selectively activate Vγ9+ γδ T cells as judged by CD69 and CD25 surface expression, and intracellular Granzyme B expression, (b) selectively recruit Vγ9+ γδ T cells into cell-cell conjugate formation of γδ T cells with tumor cells indicating selective and effective engagement of effector and target tumor cells, and (c) mediate γδ T cell cytotoxicity (in vitro and in vivo) against tumor antigen-expressing cells. Collectively, these findings suggest that selectively redirecting Vγ9+ γδ T cells to target AML blasts has a potential for immunotherapy for AML patients and favors further exploration of this concept.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ganesan R, Chennupati V, Ramachandran B, et al. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia. 2021. PMID: 33526858. doi:10.1038/s41375-021-01122-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。